Monthly Archives: May 2012
Too Much Sauce Hollandaise? Pharma, France, and Socialism
Will France’s new socialist president, François Hollande, prove too strong for pharma’s taste? Reflector, Pharm Exec’s EU correspondent, reports.
So it has happened. A leading European country has gone against the predominant political grain, and elected a socialist head of state. France is now ruled by François Hollande, a mild-mannered but avowedly drug-industry-skeptical president. Is the [...]
Posted in Global, Guest Blog Tagged euro, European Union, eurozone, France, Francois Hollande, socialist Leave a comment
Show Me the Money: Exploring Physician Incentive Compensation
A new report from ZS Associates explores the efficacy and impact of physician incentive compensation on the delivery of quality care; when incentives fall short, so can patient outcomes.
Posted in Op-Ed, Strategy Tagged ACOs, physician incentive compensation, ZS Associates Leave a comment
Will WHO Member States Pony Up for Neglected Diseases?
Recognizing that traditional market forces – namely incentives related to intellectual property and a steady demand for products – have failed in developing countries, the World Health Organization (WHO) asked a member state-nominated group to come up with ways to fund R&D and pay for the treatment of neglected diseases in the world’s poorest nations. [...]
Posted in Emerging Markets, Global, IP, Legal, Manufacturing, Market Access, R&D, leadership, pricing Tagged developing countries, developing nations, funding, neglected diseases, Neglected Tropical Diseases, Novartis, Paul Herrling, R&D, tropical diseases, WHO, World Health Assembly Leave a comment
Clayton Christensen on the Future of Pharma
A keynote speaker at the 9thAnnual SaS Health Care & Life Sciences Executive Conference on May 10, ‘disruptive’ author of The Innovator’s Dilemma and Harvard business professor Clayton Christensen sat down with PharmExec to discuss the future of the pharmaceutical industry, and what Mitt Romney could bring to the White House.
Posted in Biotech, Events, FDA, IP, People, R&D, Regulatory, Safety, Technology, Uncategorized, healthcare, leadership Tagged business model, change, Clayton Christensen, commercial model, conference, FDA, health analytics, innovation, Mitt Romney, Politics, public policy, SaS, Strategy 1 Comment

C-Suiters: Don't Look Down On Your Middle